127 related articles for article (PubMed ID: 21315272)
1. Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative.
Ocak M; Helbok A; von Guggenberg E; Ozsoy Y; Kabasakal L; Kremser L; Decristoforo C
Nucl Med Biol; 2011 Feb; 38(2):171-9. PubMed ID: 21315272
[TBL] [Abstract][Full Text] [Related]
2. The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y.
Maurin M; Garnuszek P; Baran P; Pawlak D; Mikołajczak R
Nucl Med Rev Cent East Eur; 2015; 18(2):51-5. PubMed ID: 26315862
[TBL] [Abstract][Full Text] [Related]
3. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
4. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
5. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
6. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
7. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.
Grob NM; Behe M; von Guggenberg E; Schibli R; Mindt TL
J Pept Sci; 2017 Jan; 23(1):38-44. PubMed ID: 28054429
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of a novel (177)Lu-DOTA-[Gly(3)-cyclized(Dap(4), (d)-Phe(7), Asp(10))-Arg(11)]α-MSH(3-13) analogue for melanocortin-1 receptor-positive tumor targeting.
Lim JC; Hong YD; Kim JJ; Choi SM; Baek HS; Choi SJ
Cancer Biother Radiopharm; 2012 Oct; 27(8):464-72. PubMed ID: 22831553
[TBL] [Abstract][Full Text] [Related]
9. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
10. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607.
Ocak M; Helbok A; Rangger C; Peitl PK; Nock BA; Morelli G; Eek A; Sosabowski JK; Breeman WA; Reubi JC; Decristoforo C
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1426-35. PubMed ID: 21528387
[TBL] [Abstract][Full Text] [Related]
11. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.
Hörmann AA; Klingler M; Rezaeianpour M; Hörmann N; Gust R; Shahhosseini S; Guggenberg EV
Molecules; 2020 Oct; 25(19):. PubMed ID: 33049999
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
Giblin MF; Sieckman GL; Shelton TD; Hoffman TJ; Forte LR; Volkert WA
Nucl Med Biol; 2006 May; 33(4):481-8. PubMed ID: 16720239
[TBL] [Abstract][Full Text] [Related]
13. Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate.
Petrik M; Laznickova A; Laznicek M; Zalutsky MR
Anticancer Res; 2007; 27(6B):3941-6. PubMed ID: 18225554
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
[TBL] [Abstract][Full Text] [Related]
15. Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptor.
Kolenc Peitl P; Tamma M; Kroselj M; Braun F; Waser B; Reubi JC; Sollner Dolenc M; Maecke HR; Mansi R
Bioconjug Chem; 2015 Jun; 26(6):1113-9. PubMed ID: 25971921
[TBL] [Abstract][Full Text] [Related]
16. Oxidant and Antioxidant Effects of Gentisic Acid in a
Trindade V; Balter H
Curr Radiopharm; 2020; 13(2):107-119. PubMed ID: 31526356
[TBL] [Abstract][Full Text] [Related]
17. In vitro metabolic stability of iodinated obestatin peptides.
De Spiegeleer B; Van Dorpe S; Vergote V; Wynendaele E; Pauwels E; Van De Wiele C; Garcia-Solis P; Solis-Sainz JC
Peptides; 2012 Feb; 33(2):272-8. PubMed ID: 22222609
[TBL] [Abstract][Full Text] [Related]
18. Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements
Klingler M; Hörmann AA; Rangger C; Desrues L; Castel H; Gandolfo P; von Guggenberg E
J Med Chem; 2020 Dec; 63(23):14668-14679. PubMed ID: 33226806
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM).
Wunderlich G; Schiller E; Bergmann R; Pietzsch HJ
Nucl Med Biol; 2010 Nov; 37(8):861-7. PubMed ID: 21055615
[TBL] [Abstract][Full Text] [Related]
20. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.
Sosabowski JK; Matzow T; Foster JM; Finucane C; Ellison D; Watson SA; Mather SJ
J Nucl Med; 2009 Dec; 50(12):2082-9. PubMed ID: 19910426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
